

Forum Discussions

These novel Fora, in WEF-style format, will bring together corporate participants, neuroscientists and clinicians with outstanding experience in “hottest” research topics in the field of neurodegeneration to discuss the impact of newest preclinical results and cutting edge clinical findings on understanding and treatment development of neurodegenerative disorders. The objective is to exchange novel insights, challenges and solutions on the joint path forward to defining the future of Alzheimer’s and Parkinson’s therapeutics.

Each forum will be a moderated discussion with maximum 3 minutes introduction statement from each participant followed by questions from the audience. The forum is also open for journalists from different media, including lay press in and may report on progress made by the leaders in this field.

Forum Date & Title	Co-Moderators	Discussants
Wednesday, March 29, 2023 14:45-15:45 BLOOD-BASED BIOMARKERS COMPARISON TO CSF AND IMAGING BIOMARKERS. ASSESSMENT FOR DIAGNOSES & TREATMENT EFFECTS: HOW TO MEASURE MINIMAL CLINICAL EFFICACY?	Melissa Murray (USA) Oskar Hansson (Sweden)	Agneta Nordberg (Sweden) Danielle Graham (USA) Ivonne Suridjan (Switzerland) John Sims (USA) Nick Fox (UK) Michelle Mielke (USA)

<p>Wednesday, March 29, 2023 15:55-16:55 IMMUNOTHERAPIES IN AD: FROM BASICS TO APPROVAL</p>	<p>Susanne Hendrix (USA) Robert Vassar (USA)</p>	<p>Wagner Zago (USA) Johannes Streffer (Switzerland) Janice Smith (UK) Alfred Sandrock (USA) Christian Haass (Germany) Yaning Wang (USA) Michael Irizarry (USA) Samantha Budd- Haeberlein (USA)</p>
<p>Thursday, March 30, 2023 16:20-17:20 PHASE I-III IN AD: DRUG DEVELOPMENT AND RELEVANCE FOR HETEROGENEITY OF THE DISEASE</p>	<p>Angela Genge (Canada) Jeffrey Cummings (USA)</p>	<p>Manfred Windisch (Austria) Szofia Bullain (Switzerland) Howard Fillit (USA) Michael Irizarry (USA) Todd Golde (USA) Ezio Giacobini (Switzerland)</p>
<p>Thursday, March 30, 2023 17:25-18:25 NEW INSIGHTS IN THE DEVELOPMENT OF BIOMARKERS, IMAGING AND THERAPY OF ALPHA- SYNUCLEIN, LRKK2, AND GBA PATHOLOGIES</p>	<p>Jamie Eberling (USA) Walter Koroshetz (USA)</p>	<p>Fabrizio Stocchi (Italy) John Growdon (USA) Pamela J. McLean (USA) Gennaro Pagano (Switzerland) Warren Hirst (USA)</p>

Friday, March 31, 2023 16:20-17:20 ANTI-TAU THERAPIES IN CLINICAL TRIALS	Marc Diamond (USA) Virginia Lee (USA)	Jaren Landen (USA) Phillip Dolan (USA) Edmond Teng (USA) Tomislav Babic (Austria) Larisa Reyderman (USA)
Saturday, April 1, 2023 14:45-15:45 DRUG DEVELOPMENT & BIOMARKERS IN RARE CNS DISEASES (ALS, FTD): FROM BASICS TOWARDS APPROVAL	Laura Ranum (USA) Nicholas Ashton (Sweden)	Rudy Tanzi (USA) Angela Genge (Canada) Lahar Mehta (USA) Klaus Gerwert (Germany) Mary Sano (USA) Samantha Budd- Haeberlein (USA)